Keytruda pembrolizumab: Additional Phase Ib data

Data from 26 heavily pretreated patients with salivary gland carcinoma in the open-label, international Phase Ib KEYNOTE-028 trial showed that 10 mg/kg IV Keytruda every 2 weeks for up

Read the full 290 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE